New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials | CNN
Sanofi and GSK's Vidprevtyn, a protein subunit Covid-19 vaccine, shows promising phase 3 trial results, with 58% efficacy against symptoms, 75% against moderate/severe disease, and 100% against severe disease. It's effective as a booster, increasing antibodies 18-30 fold. Plans to seek US and EU authorization, with 100 million doses already produced.
Reference News
New Sanofi and GSK vaccine demonstrates strong protection against severe Covid-19 in clinical trials | CNN
Sanofi and GSK's Vidprevtyn, a protein subunit Covid-19 vaccine, shows promising phase 3 trial results, with 58% efficacy against symptoms, 75% against moderate/severe disease, and 100% against severe disease. It's effective as a booster, increasing antibodies 18-30 fold. Plans to seek US and EU authorization, with 100 million doses already produced.